DuoResp Spiromax 160 ug / 4.5 ug
DuoResp Spiromax 160 ug / 4.5 ug is a medicine authorised by Swissmedic under authorisation number 70193. The authorisation holder is Teva Pharma AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 02 April 2026 and the authorisation is limited until 01 April 2031. ATC code R03AK07 places the medicine in the group Drugs for obstructive airway diseases.
| Authorisation number | 70193 |
|---|---|
| Name | DuoResp Spiromax 160 ug / 4.5 ug |
| Full name | DuoResp Spiromax 160 ug / 4.5 ug, Pulver zur Inhalation |
| Authorisation holder | Teva Pharma AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | R03AK07 |
| First authorisation | 02 April 2026 |
| Authorisation validity | 01 April 2031 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | DuoResp Spiromax 160 ug / 4.5 ug, Pulver zur Inhalation | B | 02 April 2026 |
| 2 | DuoResp Spiromax 320 ug / 9 ug, Pulver zur Inhalation | B | 02 April 2026 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 120 | Einzeldose(n) | R03AK07 | 03.04.3. | B |
| 2 | 3 x 120 | Einzeldose(n) | R03AK07 | 03.04.3. | B |
| 3 | 60 | Einzeldose(n) | R03AK07 | 03.04.3. | B |
| 4 | 3 x 60 | Einzeldose(n) | R03AK07 | 03.04.3. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is DuoResp Spiromax 160 ug / 4.5 ug authorised in Switzerland?
Yes. DuoResp Spiromax 160 ug / 4.5 ug is authorised by Swissmedic under authorisation number 70193, data as of 01 September 2026. The authorisation is limited until 01 April 2031.
Which dispensing category does DuoResp Spiromax 160 ug / 4.5 ug have?
DuoResp Spiromax 160 ug / 4.5 ug is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of DuoResp Spiromax 160 ug / 4.5 ug?
The authorisation holder is Teva Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.